XM does not provide services to residents of the United States of America.
Z
Z

Zimmer

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Zimmer Biomet Receives FDA Clearance For ROSA Shoulder System

BRIEF-Zimmer Biomet Receives FDA Clearance For ROSA Shoulder System Feb 22 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET RECEIVES FDA CLEARANCE FOR ROSA® SHOULDER SYSTEM - THE WORLD'S FIRST ROBOTIC ASSISTANT FOR SHOULDER REPLACEMENT SURGERY ZIMMER BIOMET HOLDINGS INC - ROSA SHOULDER WILL BE COMMERCIALLY AVAILABLE IN U.S. IN SECOND H
Z

Zimmer Biomet Announces Quarterly Dividend For First Quarter Of 2024

BRIEF-Zimmer Biomet Announces Quarterly Dividend For First Quarter Of 2024 Feb 21 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET ANNOUNCES QUARTERLY DIVIDEND FOR FIRST QUARTER OF 2024 ZIMMER BIOMET HOLDINGS : CASH DIVIDEND OF $0.24/SHARE PAYABLE ON APRIL 30, 2024 TO STOCKHOLDERS OF RECORD AS OF CLOSE OF BUSINESS ON MARCH 29, 2024 Sour
Z

Zimmer Biomet Holdings Inc reports results for the quarter ended in December - Earnings Summary

Zimmer Biomet Holdings Inc reports results for the quarter ended in December - Earnings Summary Zimmer Biomet Holdings Inc ZBH.N reported quarterly adjusted earnings of $2.20​​ per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $1.88. The mean expectation of twenty five analysts for the quarter was for earnings of $2.15 per share.
Z

Zimmer Biomet forecasts upbeat 2024 profit on steady medical devices demand

Zimmer Biomet forecasts upbeat 2024 profit on steady medical devices demand Feb 8 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N forecast 2024 profit above Wall Street expectations on Thursday, betting on resilient demand for its medical devices, and said it had initiated a restructuring program late last year to cut costs. The company expects run-rate savings of about $200 million by 2025 through the initiative.
A
Z

Zimmer Biomet Announces Fourth Quarter And Full-Year 2023 Financial Results

BRIEF-Zimmer Biomet Announces Fourth Quarter And Full-Year 2023 Financial Results Feb 8 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 FINANCIAL RESULTS : SEES 2024 REPORTED REVENUE CHANGE OF 4.5% - 5.5% : SEES 2024 ADJUSTED DILUTED EPS BETWEEN $8.00 - $8.15 ZIMMER BIOMET HOLDINGS - INITIATE
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.